Home › Conditions › Hypercalcaemia
Endocrine
Hypercalcaemia
Adjusted calcium · mmol/L
Hypercalcaemia: adjusted calcium >2.6 mmol/L. Mild <3.0 (often asymptomatic), moderate 3.0–3.5, severe >3.5 (medical emergency). Causes: 90% either primary hyperparathyroidism (outpatient, usually mild) or malignancy (bone mets, PTHrP secretion — usually severe). Mnemonic: 'Bones, Stones, Groans, Moans, Psychic Tones'. ECG: short QT.
NICE / Society for Endocrinology Hypercalcaemia Management
The pathway
Symptoms & severity
- Bones (bone pain, pathological fractures)
- Stones (renal calculi, nephrocalcinosis)
- Groans (nausea, vomiting, constipation, pancreatitis)
- Moans (depression, cognitive slowing)
- Psychic Tones (confusion, psychosis, coma)
- ECG: short QTc, long PR, broad QRS
- Severe >3.5: confusion, cardiac arrhythmias
Confirm and investigate cause
- Adjusted Ca2+ (if albumin low, use formula: Ca2+ + [0.02 × (40 - albumin)])
- PTH level: high/inappropriately normal PTH = PTH-dependent: consider primary hyperparathyroidism, FHH and tertiary disease, low PTH = PTH-independent: investigate malignancy and other causes
- PTHrP: malignancy
- 25-OH vitamin D: deficiency/excess; 1,25-(OH)₂D if granulomatous disease (sarcoidosis, TB) or lymphoma suspected
- Myeloma screen: protein electrophoresis, Bence-Jones protein, serum free light chains
IV fluid rehydration
- 0.9% NaCl 200–300ml/hr initially for acute severe hypercalcaemia with volume depletion. Hypercalcaemia can cause nephrogenic diabetes insipidus, causing polyuria and dehydration. Aim for UO 100–150ml/hr
- Avoid diuretics initially; use loop diuretics only for fluid overload, not to lower calcium
- Reassess fluid status frequently; reduce the rate in heart/renal failure or if overload develops
Bisphosphonate therapy
- Zoledronic acid 4mg IV over 15 min (or pamidronate 60–90mg over 4h) — inhibits osteoclast-mediated bone resorption
- Takes 24–48h to have effect
- Most effective for malignancy-related hypercalcaemia
- Check creatinine before treatment. For tumour-induced hypercalcaemia, severe renal impairment needs specialist risk–benefit assessment; do not apply an eGFR 35 cut-off
- Effect lasts 2–4 weeks
Other agents
- Calcitonin 4 IU/kg IM/SC: rapid onset (hours), useful as bridge while waiting for bisphosphonate effect. Limit to 48–72 h because of tachyphylaxis.
- Denosumab: for bisphosphonate-refractory cases.
- Corticosteroids: for sarcoidosis, lymphoma, vitamin D toxicity.
- Dialysis: for renal failure + severe hypercalcaemia.
Treat the underlying cause
- Primary hyperparathyroidism: refer for surgery if symptomatic, adjusted Ca ≥2.85, renal stones, fragility fracture or osteoporosis; consider referral even without these
- Malignancy: treat cancer, bisphosphonates for bone mets
- Sarcoidosis: steroids
- Stop thiazides and excess calcium/vitamin D
- In PHPT, check vitamin D and replace deficiency with monitoring
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| 0.9% NaCl | 200–300ml/hr | IV | Rehydrate volume depletion; target UO 100–150ml/hr. Reassess frequently; reduce rate in heart/renal failure or fluid overload. |
| Zoledronic acid | 4mg over 15 min | IV | Check creatinine first. Onset 24–48h. In tumour-induced hypercalcaemia the SmPC needs no dose adjustment below creatinine 400 µmol/L; severe renal impairment is a risk–benefit decision, not a bar. The CrCl <35 ml/min contraindication applies to Aclasta 5mg (osteoporosis/Paget’s), not this tumour-hypercalcaemia regimen. |
| Pamidronate | 60–90mg over 4h | IV | Alternative IV bisphosphonate (longer infusion). Zoledronate gives higher calcium-response rates. Adjust for renal function. |
| Calcitonin | 4 IU/kg 12-hourly | IM/SC | Acts in 4–6 h. Bridge to IV bisphosphonate; max 48–72 h because of tachyphylaxis. |
When to escalate
- Ca2+ >3.5 → urgent correction; confusion/arrhythmia are danger signs. ITU if compromised
- Malignancy-related hypercalcaemia → oncology input urgently
- AKI with severe hypercalcaemia → nephrology, consider dialysis
- Ca2+ not falling with bisphosphonate → denosumab, haematology/oncology
- Primary hyperparathyroidism confirmed → endocrine surgery referral
Reference: NICE CKS Hypercalcaemia / Society for Endocrinology: Emergency management of acute hypercalcaemia in adults (2016)
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.